OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gomella on the Cost of the Immunotherapy Sipuleucel-T

March 1st 2012

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T

Dr. Jagannath on HDAC Inhibitors for Multiple Myeloma

February 29th 2012

Dr. Sundar Jagannath from the Tisch Cancer Institute Discusses HDAC Inhibitors for Multiple Myeloma

Dr. Solin on Personalizing Treatment With the DCIS Score

February 28th 2012

Dr. Lawrence Solin from Einstein Medical Center on Personalizing Treatment With the DCIS Score

Dr. Petrylak Discusses the Isotope Radium-223

February 28th 2012

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Isotope Radium-223

Dr. Burris on Using Recurrence Scores to Predict pCR

February 23rd 2012

Dr. Howard Burris from Sarah Cannon Research Institute Discusses Recurrence Scores Predicting pCR

Dr. Perez Discusses Optimizing Adjuvant Therapy

February 22nd 2012

Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses Optimizing Adjuvant Therapy

Dr. Schnabel on Predicting Breast Cancer by Atypia Type

February 21st 2012

Dr. Freya Schnabel from NYU School of Medicine on Predicting Breast Cancer by Atypia Type

Dr. Harvey on Aromatase Inhibitor Treatment Duration

February 20th 2012

Dr. Harold Harvey from Penn State Hershey Cancer Institute on Aromatase Inhibitor Treatment Duration

Dr. Leyland-Jones Discusses Genome Sequencing

February 20th 2012

Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing

Dr. Bloom Explains Situations Requiring HER2 Retesting

February 16th 2012

Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting

Dr. Gomella Discusses the NeoACT Sipuleucel-T Study

February 15th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the NeoACT Sipuleucel-T Study

Dr. Perez-Soler on Treatment Options for NSCLC

February 14th 2012

Dr. Roman Perez-Soler, from Montefiore Medical Center, on Treatment Options for NSCLC

Dr. Ramaswamy on Dormant Tumor Cells and Resistance

February 13th 2012

Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Dormant Tumor Cells and Resistance

Dr. Hamlin on Integrating Brentuximab Vedotin

February 10th 2012

Dr. Paul Hamlin, from Memorial Sloan-Kettering Cancer Center, Discusses Integrating Brentuximab Vedotin

Dr. Rosenbloom on Gaucher Disease Diagnosis Challenges

February 10th 2012

Dr. Barry Rosenbloom, from the Comprehensive Gaucher Treatment Center, on Gaucher Disease Diagnosis Challenges

Dr. Berenson on Zometa as the Gold Standard for Myeloma

February 9th 2012

Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM

Dr. Burris Discusses the Stratification of Clinical Trials

February 8th 2012

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials

Dr. Perez Describes Retesting Recurrent Breast Cancer

February 7th 2012

Dr. Edith Perez, from the Mayo Clinic Cancer Center, Describes Retesting Recurrent Breast Cancer

Dr. Baselga on the Basis Behind the BOLERO-2 Trial

February 7th 2012

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Dr. Cohen on mTOR Inhibition in Head and Neck Cancer

February 3rd 2012

Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer